Development and internal validation of an inflammation-platelet synergy score for anterior circulation cerebral infarction: an exploratory case-control study - Report - MDSpire
Advertisement
Development and internal validation of an inflammation-platelet synergy score for anterior circulation cerebral infarction: an exploratory case-control study
Clinical Report: Creation and internal assessment of a synergy score for inflammation and platelets in anterior circulation stroke
Overview
This study developed and validated an inflammation-platelet synergy score to distinguish patients with anterior circulation cerebral infarction from high-risk controls. The score demonstrated good discriminative ability.
Background
Ischemic stroke is a leading cause of mortality and disability worldwide, with anterior circulation cerebral infarction being the most common subtype. Understanding the interplay between inflammatory and thrombotic pathways is crucial for improving risk assessment and management strategies in stroke patients. This study explores a novel synergy score that combines multiple biomarkers.
Data Highlights
Parameter
Cases (Median)
Controls (Median)
p-value
CRP (mg/L)
6.2
3.5
< 0.001
MPV (fL)
10.64
9.64
< 0.001
IMT (mm)
1.16
0.90
< 0.001
Key Findings
The synergy score included six parameters: CRP, MPV, PDW, platelet count, IMT, and unstable plaque status.
The score demonstrated an AUC of 0.824, indicating good discriminative ability for anterior circulation cerebral infarction.
Cerebral infarction prevalence increased from 36.0% in low-risk to 87.2% in high-risk groups.
Higher synergy scores were associated with greater stroke severity and unfavorable functional outcomes at discharge.
Clinical Implications
Further prospective validation is necessary before clinical application can be considered.
Conclusion
Further investigation is warranted for the clinical utility of the inflammation-platelet synergy score.
